167 related articles for article (PubMed ID: 34712771)
1. Soluble suppression of tumorigenicity 2 (sST2) for predicting disease severity or mortality outcomes in cardiovascular diseases: A systematic review and
Ip C; Luk KS; Yuen VLC; Chiang L; Chan CK; Ho K; Gong M; Lee TTL; Leung KSK; Roever L; Bazoukis G; Lampropoulos K; Li KHC; Tse G; Liu T;
Int J Cardiol Heart Vasc; 2021 Dec; 37():100887. PubMed ID: 34712771
[TBL] [Abstract][Full Text] [Related]
2. The association between soluble suppression of tumorigenicity-2 and long-term prognosis in patients with coronary artery disease: A meta-analysis.
Liu N; Hang T; Gao X; Yang W; Kong W; Lou Q; Yang J
PLoS One; 2020; 15(9):e0238775. PubMed ID: 32886697
[TBL] [Abstract][Full Text] [Related]
3. Prognostic role of soluble suppression of tumorigenicity-2 on cardiovascular mortality in outpatients with heart failure.
Gül İ; Yücel O; Zararsız A; Demirpençe Ö; Yücel H; Zorlu A; Yılmaz MB
Anatol J Cardiol; 2017 Sep; 18(3):200-205. PubMed ID: 28761021
[TBL] [Abstract][Full Text] [Related]
4. Association of soluble suppression of tumorigenicity 2 with mortality and adverse outcomes in chronic kidney disease: a systematic review and meta-analysis.
Bellos I; Marinaki S; Lagiou P; Benetou V
Clin Exp Nephrol; 2024 Apr; ():. PubMed ID: 38678167
[TBL] [Abstract][Full Text] [Related]
5. Increased Plasma Concentrations of Soluble ST2 Independently Predict Mortality but not Cardiovascular Events in Stable Coronary Heart Disease Patients: 13-Year Follow-up of the KAROLA Study.
Pfetsch V; Sanin V; Jaensch A; Dallmeier D; Mons U; Brenner H; Koenig W; Rothenbacher D
Cardiovasc Drugs Ther; 2017 Apr; 31(2):167-177. PubMed ID: 28283847
[TBL] [Abstract][Full Text] [Related]
6. Short-term and long-term prognostic value of circulating soluble suppression of tumorigenicity-2 concentration in acute coronary syndrome: a meta-analysis.
Gu L; Li J
Biosci Rep; 2019 Jun; 39(6):. PubMed ID: 31092701
[No Abstract] [Full Text] [Related]
7. Prognostic Value of Soluble Suppression of Tumorigenicity-2 in Chronic Heart Failure: A Meta-Analysis.
Aimo A; Vergaro G; Passino C; Ripoli A; Ky B; Miller WL; Bayes-Genis A; Anand I; Januzzi JL; Emdin M
JACC Heart Fail; 2017 Apr; 5(4):280-286. PubMed ID: 27816512
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of soluble ST2 postaortic valve replacement: a meta-analysis.
Tse G; Ip C; Luk KS; Gong M; Ting YY; Lakhani I; Bazoukis G; Li G; Letsas KP; Dong M; Liu T; Wong MCS
Heart Asia; 2018; 10(1):e010980. PubMed ID: 29636828
[TBL] [Abstract][Full Text] [Related]
9. Predicting long-term cardiovascular outcomes of patients with acute myocardial infarction using soluble ST2.
Somuncu MU; Kalayci B; Avci A; Akgun T; Karakurt H; Demir AR; Avci Y; Can M
Horm Mol Biol Clin Investig; 2020 Feb; 41(2):. PubMed ID: 32112700
[TBL] [Abstract][Full Text] [Related]
10. Prognostic Value of Soluble Suppression of Tumorigenicity 2 in Chronic Kidney Disease Patients: A Meta-Analysis.
Guo G; Huang A; Huang X; Xu T; Yao L
Dis Markers; 2021; 2021():8881393. PubMed ID: 33574967
[TBL] [Abstract][Full Text] [Related]
11. Association of Soluble Suppression of Tumorigenicity with No-Reflow Phenomenon and Long-Term Prognosis in Patients with Non-ST-Segment Elevation Acute Coronary Syndrome after Percutaneous Coronary Intervention.
Zhang Q; Hu M; Ma S
J Atheroscler Thromb; 2021 Dec; 28(12):1289-1297. PubMed ID: 33551392
[TBL] [Abstract][Full Text] [Related]
12. Circulating sST2 and catestatin levels in patients with acute worsening of heart failure: a report from the CATSTAT-HF study.
Borovac JA; Glavas D; Susilovic Grabovac Z; Supe Domic D; Stanisic L; D'Amario D; Kwok CS; Bozic J
ESC Heart Fail; 2020 Oct; 7(5):2818-2828. PubMed ID: 32681700
[TBL] [Abstract][Full Text] [Related]
13. Increased soluble ST2 predicts long-term mortality in patients with stable coronary artery disease: results from the Ludwigshafen risk and cardiovascular health study.
Dieplinger B; Egger M; Haltmayer M; Kleber ME; Scharnagl H; Silbernagel G; de Boer RA; Maerz W; Mueller T
Clin Chem; 2014 Mar; 60(3):530-40. PubMed ID: 24401186
[TBL] [Abstract][Full Text] [Related]
14. Long-Term and Short-Term Prognostic Value of Circulating Soluble Suppression of Tumorigenicity-2 Concentration in Chronic Heart Failure: A Systematic Review and Meta-Analysis.
Dong G; Chen H; Zhang H; Gu Y
Cardiology; 2021; 146(4):433-440. PubMed ID: 33902050
[TBL] [Abstract][Full Text] [Related]
15. Meta-Analysis of Soluble Suppression of Tumorigenicity-2 and Prognosis in Acute Heart Failure.
Aimo A; Vergaro G; Ripoli A; Bayes-Genis A; Pascual Figal DA; de Boer RA; Lassus J; Mebazaa A; Gayat E; Breidthardt T; Sabti Z; Mueller C; Brunner-La Rocca HP; Tang WH; Grodin JL; Zhang Y; Bettencourt P; Maisel AS; Passino C; Januzzi JL; Emdin M
JACC Heart Fail; 2017 Apr; 5(4):287-296. PubMed ID: 28189578
[TBL] [Abstract][Full Text] [Related]
16. sST2 levels are associated with all-cause mortality in anticoagulated patients with atrial fibrillation.
Vílchez JA; Pérez-Cuellar M; Marín F; Gallego P; Manzano-Fernández S; Valdés M; Vicente V; Noguera-Velasco JA; Lip GY; Ordóñez-Llanos J; Roldán V
Eur J Clin Invest; 2015 Sep; 45(9):899-905. PubMed ID: 26081996
[TBL] [Abstract][Full Text] [Related]
17. Superior prognostic value of soluble suppression of tumorigenicity 2 for the short-term mortality of maintenance hemodialysis patients compared with NT-proBNP: a prospective cohort study.
Wang Z; Chen Z; Yu H; Ma X; Zhang C; Qu B; Zhang W; Chen X
Ren Fail; 2020 Nov; 42(1):523-530. PubMed ID: 32460670
[No Abstract] [Full Text] [Related]
18. Role of the IL-33/ST2 axis in cardiovascular disease: A systematic review and meta-analysis.
Sun Y; Pavey H; Wilkinson I; Fisk M
PLoS One; 2021; 16(11):e0259026. PubMed ID: 34723980
[TBL] [Abstract][Full Text] [Related]
19. Predictive value of soluble suppression of tumorigenicity 2 in atrial fibrillation: a systematic review and meta-analysis.
Chen P; Zhang J; Du J; Shi D; Zhang H
Front Cardiovasc Med; 2023; 10():1308166. PubMed ID: 38274310
[TBL] [Abstract][Full Text] [Related]
20. Circulating Soluble ST2 Predicts All-Cause Mortality in Severe Heart Failure Patients with an Implantable Cardioverter Defibrillator.
Hou ZW; Yu HB; Liang YC; Gao Y; Xu GQ; Wu M; Mei Z; Wang ZL; Li ZG; Li YY; Song HX; Li JY; Han YL
Cardiol Res Pract; 2020; 2020():4375651. PubMed ID: 33282418
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
